Skip to main content
. 2020 Nov 19;133(24):2998–3000. doi: 10.1097/CM9.0000000000001232

Figure 1.

Figure 1

Comparison of the median time to relapse among different biologics. (A) Head-to-head comparison of time to relapse (PGA ≥ 3) between etanercept and ustekinumab (left); head-to-head comparison of time to relapse (initiation of new systemic treatment) between secukinumab and guselkumab (right). (B) Time to relapse (loss of PASI 50) in individual studies. (C) Time to relapse (PGA ≥ 3) in individual studies. IL: Interleukin; PASI: Psoriasis Area and Severity Index; PGA: Physician's Global Assessment score; TNF: Tumor necrosis factor.